QT Imaging Earnings Call: Rapid Growth Meets Tight Margins

Qt Imaging Holdings, Inc. ((QTI)) has held its Q1 earnings call. Read on for the main highlights of the call.

QT Imaging Holdings’ latest earnings call balanced strong commercial traction with lingering financial strain. Management highlighted triple-digit revenue growth, accelerating unit shipments and deepening distributor commitments across key geographies. Yet investors also heard a candid assessment of margin compression, rising operating costs, limited cash and higher borrowing expenses that continue to weigh on the bottom line.

Surging Top-Line Momentum on Scanner Shipments

QT Imaging posted Q1 2026 revenue of $6.5 million, a 133% jump versus the prior-year quarter. The advance was driven largely by increased scanner volumes, with 13 QT Breast Acoustic CT systems shipped versus six a year earlier, signaling rapid commercial uptake of the company’s imaging platform.

Commercial Execution and Global Rollout

The shipment of 13 systems in the quarter was described as in line with distribution commitments and reflected rising activity in both U.S. and overseas markets. Management framed the performance as evidence that its sales channels are beginning to scale, setting a foundation for sustained growth as new regions open.

Multi-Year Distribution Contracts Build Revenue Visibility

Investors received detail on sizable multi-year distributor deals that underpin the growth story. NXC Imaging has contracted for 60 scanners in 2026, while Gulf Medical and Al Naghi Medical together represent more than $75 million in potential revenue through 2028, giving the company an unusually robust committed backlog.

Regulatory Wins and Reimbursement Pathway

On the regulatory front, the company secured a new Category III CPT code from the American Medical Association, effective in 2027, which should aid utilization tracking and eventual reimbursement. QT Imaging also obtained FDA 510(k) clearance for enhancements aimed at better posterior breast visualization and gained UAE clearance for both its scanner and SaaS platform.

Product and Software Upgrades Enhance Clinical Offering

Management highlighted the launch of the QT Imaging-Olea Viewer to support multi-modality imaging and longitudinal patient review. A new software release, version 4.5.0, was said to deliver roughly 40–50% better reflection image resolution across all axes, improving spatial detail and potentially boosting calcification detection.

Growing Clinical Validation and Advisory Bench Strength

Clinical data were a central theme, with a Mayo Clinic feasibility study showing absolute agreement between QTscan and MRI in high-risk supplemental screening. The company also cited forthcoming Sunnybrook results on volumetric therapy monitoring and the addition of senior clinical advisers to refine strategy, training and deployment.

Loss Narrowing and EBITDA Trend Improvement

Despite ongoing losses, profitability metrics improved sharply year over year, with net loss shrinking to $3.4 million from $11.1 million. EBITDA also moved in the right direction, improving to negative $2.5 million versus negative $10.4 million, suggesting early operating leverage as volumes build.

Debt Extension Adds Flexibility but at Higher Cost

QT Imaging extended the maturity of its $10.1 million senior secured term loan by two years to March 31, 2029, easing near-term balance sheet pressure. However, the interest rate on that facility was raised from 10% to 12%, increasing future interest expense and partially offsetting the benefit of additional runway.

Margin Compression Highlights Cost and Mix Challenges

The quarter’s primary red flag was a steep gross margin decline to 41% from 65% a year earlier, driven by a jump in cost of revenue to $3.9 million. Management noted that prior-year margins benefited from selling scanners with a lower cost basis, underscoring how product mix and unit cost will heavily influence margins during the scale-up phase.

Operating Expense Growth and Adjusted EBITDA Pressure

Total operating expenses climbed to $5.0 million from $2.9 million, reflecting higher compensation and professional fees as the company builds out its commercial and clinical infrastructure. Adjusted EBITDA, which strips out noncash items, worsened to a loss of $1.5 million versus a $903,000 loss, indicating underlying operating performance remains under pressure.

Cash Burn, Limited Liquidity and Financing Risk

Net cash used in operating activities totaled $3.7 million, roughly in line with the prior year’s $3.5 million burn rate. With only $7.0 million in cash, restricted cash and equivalents at quarter-end, QT Imaging faces a relatively short liquidity runway and may need to tap capital markets or further financing if cash generation does not improve quickly.

Regulatory and Geopolitical Execution Risks

Management acknowledged that regulatory timing and geopolitics pose real near-term risks to its growth plan, particularly in the Middle East. Saudi FDA approval remains outstanding and some shipments into regional markets are being delayed by conflict-related disruptions, which could shift the timing of international revenue.

Dependence on Distributors and Product Mix for Margins

The company’s growth and earnings trajectory now hinge heavily on distributors meeting minimum order commitments and on early monetization of cloud services. At the same time, prior-year benefit from lower-cost scanners means current gross margins are very sensitive to product mix and underlying unit costs as volumes scale.

Guidance Framed by Backlog and Early Monetization Plans

QT Imaging reaffirmed its 2026 revenue outlook of about $39 million, more than double 2025 levels, citing the strength of contracted distributor minimums and planned cloud services revenue. Management argued that Q1’s revenue surge, improved loss profile and multi-year deals support the forecast, while emphasizing that execution on approvals, shipments and cost control will be critical.

QT Imaging’s call painted a picture of a company transitioning from validation to commercialization, with clear demand signals and solid regulatory progress supporting a bullish revenue outlook. For investors, the story now turns on whether management can convert its deep backlog into profitable growth while navigating tight liquidity, higher interest costs and the operational hurdles of a global rollout.